Close

UPDATE: Turing Pharma CEO Shkreli Resigns; Co. Remains Committed to Affordable Daraprim, Vecamyl Access

December 18, 2015 12:37 PM EST

(Updated - December 18, 2015 12:43 PM EST)

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today announced the resignation of Martin Shkreli from the position of Chief Executive Officer and the appointment of Ron Tilles to the position of Interim Chief Executive Officer.

Mr. Tilles will continue to serve as Chairman of the Board of Directors. He said, "We wish to thank Martin for helping us build Turing Pharmaceuticals into the dynamic research focused company it is today, and wish him the best in his future endeavors. At the same time, I am very excited about the opportunity to guide Turing Pharmaceuticals forward. We remain committed to ensuring that all patients have ready and affordable access to Daraprim and Vecamyl. Research Development on new medications continues to be a priority for the company. With the dynamic leadership of Eliseo Salinas as head of Research and Development and Nancy Retzlaff as head of Commercial Operations, Turing Pharmaceuticals is poised for great success in the coming years."

Ron Tilles has been Chairman of the Board of Directors of Turing Pharmaceuticals since the company launched late last year. Mr. Tilles began his career at Merrill Lynch in 1985 and subsequently worked with several other securities firms. Ron's experience includes numerous private equity and venture capital positions in the pharmaceutical and medical device industries over the last 20 years. He earned his undergraduate degree from Middlebury College in Vermont and his Masters of Business Administration from Columbia University in New York.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Hot Mgmt Changes, Insiders' Blog, Management Changes